Spots Global Cancer Trial Database for tepotinib
Every month we try and update this database with for tepotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | NCT06106802 | Non-Small Cell ... | Lazertinib Tepotinib | 19 Years - | Samsung Medical Center | |
| Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate | NCT03492437 | Healthy | Dabigatran Etex... Tepotinib | 18 Years - 44 Years | Merck KGaA, Darmstadt, Germany | |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | NCT01988493 | Carcinoma, Hepa... | Tepotinib 300 m... Tepotinib 500 m... Tepotinib 1000 ... Tepotinib Sorafenib | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Tepotinib in Solid Tumors Harboring MET Alterations | NCT04647838 | Solid Tumor MET Exon 14 Ski... MET Amplificati... | Tepotinib | 19 Years - | Chungbuk National University Hospital | |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | NCT06083857 | Non-small Cell ... | Amivantamab Tepotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | NCT06031688 | Recurrent Lung ... Stage IV Lung C... | Biospecimen Col... Computed Tomogr... Lymphoscintigra... Magnetic Resona... Ramucirumab Tepotinib | - | SWOG Cancer Research Network | |
| POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC | NCT05782361 | Advanced Cancer Non Small Cell ... | Tepotinib Pembrolizumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| Effect of a Proton Pump Inhibitor on the PK of Tepotinib | NCT03531762 | Healthy | Tepotinib Omeprazole | 18 Years - 55 Years | Merck KGaA, Darmstadt, Germany | |
| A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors | NCT05120960 | Brain Tumor | tepotinib tepotinib plus ... | 18 Years - | M.D. Anderson Cancer Center | |
| c-Met Second-Line Hepatocellular Carcinoma | NCT02115373 | Carcinoma, Hepa... | Tepotinib Tepotinib | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | NCT06083857 | Non-small Cell ... | Amivantamab Tepotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | NCT04515394 | Colorectal Neop... | Tepotinib Cetuximab | 18 Years - | EMD Serono | |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | NCT01988493 | Carcinoma, Hepa... | Tepotinib 300 m... Tepotinib 500 m... Tepotinib 1000 ... Tepotinib Sorafenib | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Effect of a Proton Pump Inhibitor on the PK of Tepotinib | NCT03531762 | Healthy | Tepotinib Omeprazole | 18 Years - 55 Years | Merck KGaA, Darmstadt, Germany |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
